Future Of CBD In Supplements: NDI Notification Looms As Regulatory Path

Recent statement that FDA has not found evidence supporting CBD as GRAS for use in human or animal food potentially points to NDI notifications as the only option manufacturers, marketers and other businesses will have to convince agency about safety for CBD and other hemp-derived substances used in dietary supplements.

Clock-Calendar_173563493_1200.jpg

The clock could be ticking on using cannabidiols in dietary supplements available in the US without submitting new dietary ingredient notifications that the Food and Drug Administration agrees show safety for the ingredient's intended uses.

The agency's recent statement that it is not aware of evidence supporting CBD as generally recognized as safe among qualified experts for use in human or animal food potentially points to NDI notifications as the only option that manufacturers, marketers and other businesses will have to convince the FDA about

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

More from Policy & Regulation